Project Grant R01MH140473
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded George Washington University a Project Grant of $731,738 under the Mental Health Research Grants program (CFDA 93.242), effective September 10, 2025 through September 9, 2028, to conduct a pilot feasibility study integrating pre-exposure prophylaxis (PrEP) into emergency departments (EDs) using decision support tools. The project addresses gaps in HIV prevention by developing and testing a patient-centered...
- Federal Grant Award Summary The University of Washington received a $672,701 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), effective February 15, 2026 through November 30, 2030. This research initiative implements HIV screening and prevention services integrated within low-barrier office-based opioid treatment (OBOT) programs at Harborview Medical Center in Seattle, Washington, to support the federal government's...
- Federal Project Grant Award Summary The University of Washington received a $699,750 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded May 7, 2026, with completion targeted for May 6, 2029. This award funds the adaptation and implementation of the "Do More, Feel Better" (DMFB) intervention, an evidence-based behavioral activation program designed to address depression and improve mental health...
- Federal Grant Award Summary The University of Washington received a $2.33 million Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a hybrid implementation-effectiveness study evaluating the Pharmacist, Physician, and Patient Navigator Collaborative Care Model (PPP-CCM) for hepatitis C treatment among people who use drugs with housing insecurity. Awarded on August 15, 2025, and extending through April 30, 2030, the...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $149,190 Project Grant to Columbia University's Health Sciences Division on August 9, 2026, under the Mental Health Research Grants program (CFDA 93.242) for research characterizing Pre-Exposure Prophylaxis (PrEP) need and use in Eswatini. The research will deliver epidemiological methods and analytical models to identify vulnerable HIV-positive populations most likely to benefit from PrEP interventions and...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $191,117.00 to The Regents of the University of California, San Francisco under the Mental Health Research Grants program (CFDA 93.242) effective September 1, 2025, through August 31, 2030. This K23 mentored research grant supports the development and pilot testing of PRISM-P (PrEP-Related Intervention for Stigma Mitigation Among Pharmacy Staff), an anti-stigma intervention designed to improve communication...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded the University of North Carolina at Chapel Hill a Project Grant of $691,620 on September 22, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and pilot a web-based decision support system designed to increase Pre-Exposure Prophylaxis (PrEP) awareness and utilization among women in the Southeastern United States. The three-year project (through September 21, 2028) addresses the...
- Federal Project Grant Award Summary Public Health Foundation Enterprises, Inc. (doing business as Heluna Health) received a $659,242 Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) awarded March 5, 2026, with a completion date of November 30, 2030. The project, titled "PREP BLUEPRINT: Evaluating Implementation of a PREP Choice Blueprint on PREP Uptake and Persistence," develops a scalable blueprint to assist...
- Grant Award Summary Empowerx, Inc., a woman-owned small business, received a $485,654 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) on September 22, 2025, with a completion date of August 31, 2026. The award funds the PEP/PREP via Pharmacist-Prescribing Implementation (PEPPI) project, which will develop software and implementation support to expand access to post-exposure prophylaxis (PEP) and pre-exposure...
- Federal Project Grant Award Summary Wake Forest University Health Sciences received a $3.08 million Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective July 1, 2025, with a completion date of March 31, 2030. The HIP-PHARM (Integrated HIV and Overdose Prevention in Pharmacies) project delivers research services assessing the availability and implementation of HIV pre-exposure prophylaxis (PrEP) and overdose...
The University of Washington received a $729,551 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded May 4, 2026, with completion targeted for February 28, 2031. This implementation science project addresses barriers to HIV pre-exposure prophylaxis (PrEP) access by expanding pharmacy-based PrEP services. The grant supports three primary aims: (1) building on an existing Ending the HIV Epidemic (EHE) initiative supplement to evaluate a virtual community of practice (VCOP) for pharmacists and pharmacy staff to increase their knowledge and capabilities in PrEP prescribing; and (2-3) conducting financial analyses and time-motion studies to evaluate the cost-effectiveness and operational feasibility of providing injectable PrEP versus oral medications and comparing in-pharmacy visits to telehealth delivery models. The project generates evidence-based products and findings intended to support broader implementation of pharmacy-based PrEP across the United States. Deliverables include evaluation data on the VCOP training model's effectiveness, health economics analyses providing financial projections for pharmacy PrEP implementation, and comparative cost-benefit data on injectable versus oral PrEP delivery modalities. These products will inform pharmacy practice standards, insurance coverage policies, and state regulatory frameworks to overcome existing barriers—including prescriptive authority limitations and reimbursement constraints—and increase PrEP access and continuity of treatment among populations who would benefit most from prevention services.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $729.6k | 5/6/26 |